Antioxidant Barrier, Redox Status, and Oxidative Damage to Biomolecules in Patients with Colorectal Cancer. Can Malondialdehyde and Catalase Be Markers of Colorectal Cancer Advancement?
Justyna Zińczuk,
Mateusz Maciejczyk,
Konrad Zaręba,
Wioletta Romaniuk,
Adam Markowski,
Bogusław Kędra,
Anna Zalewska,
Anna Pryczynicz,
Joanna Matowicka-Karna,
Katarzyna Guzińska-Ustymowicz
Affiliations
Justyna Zińczuk
Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Waszyngtona 15a, 15-269 Białystok, Poland
Mateusz Maciejczyk
Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, Mickiewicza 2c, 15-222 Białystok, Poland
Konrad Zaręba
2nd Clinical Department of General and Gastroenterological Surgery, Medical University of Bialystok, M. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland
Wioletta Romaniuk
Department of Haematology, Medical University of Bialystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland
Adam Markowski
Department of Internal Medicine and Gastroenterology, Polish Red Cross Memorial Municipal Hospital, Sienkiewicza 79, 15-003 Bialystok, Poland
Bogusław Kędra
2nd Clinical Department of General and Gastroenterological Surgery, Medical University of Bialystok, M. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland
Anna Zalewska
Department of Conservative Dentistry, Medical University of Bialystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland
Anna Pryczynicz
Department of General Pathomorphology, Medical University of Bialystok, Waszyngtona 13, 15-269 Białystok, Poland
Joanna Matowicka-Karna
Department of Clinical Laboratory Diagnostics, Medical University of Bialystok, Waszyngtona 15a, 15-269 Białystok, Poland
Katarzyna Guzińska-Ustymowicz
Department of General Pathomorphology, Medical University of Bialystok, Waszyngtona 13, 15-269 Białystok, Poland
This study is the first to assess the diagnostic utility of redox biomarkers in patients with colorectal cancer (CRC). Antioxidant barrier (Cu,Zn-superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), uric acid (UA), reduced glutathione (GSH)), redox status (total antioxidant (TAC)/oxidant status (TOS), ferric reducing ability (FRAP)), and oxidative damage products (advanced glycation end products (AGE), advanced oxidation protein products (AOPP), malondialdehyde (MDA)) were measured in serum/plasma samples of 50 CRC patients. The activity of SOD was significantly higher whereas the activity of CAT, GPx and GR was considerably lower in CRC patients compared to the control group (p < 0.0001). Levels of UA, TOS, and OSI and concentrations of AGE, AOPP, and MDA were significantly higher, and the levels of GSH, TAC, and FRAP were considerably lower in CRC patients compared to the healthy controls (p < 0.0001). AUC for CAT with respect to presence of lymph node metastasis was 0.7450 (p = 0.0036), whereas AUC for MDA according to the depth of tumour invasion was 0.7457 (p = 0.0118). CRC is associated with enzymatic/non-enzymatic redox imbalance as well as increased oxidative damage to proteins and lipids. Redox biomarkers can be potential diagnostic indicators of CRC advancement.
